The histone deacetylase inhibitor LBH589 inhibit undifferentiated pleomorphic sarcoma growth via downregulation of FOSL1

被引：0
|
作者：
Saitoh, Yoshinobu [1 ]
Setoguchi, Takao [1 ]
Nagano, Satoshi [1 ]
Taniguchi, Noboru [1 ]
机构：
[1] Kagoshima Univ, Dept Orthop Surg, Kagoshima, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-3419
引用
收藏
页码：1416 / 1416
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
    de Marinis, Filippo
    Atmaca, Akin
    Tiseo, Marcello
    Giuffreda, Libero
    Rossi, Antonio
    Gebbia, Vittorio
    D'Antonio, Chiara
    Dal Zotto, Laura
    Al-Batran, Salah-Eddin
    Marsoni, Silvia
    Wolf, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1091 - 1094
  • [32] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Vallo, Stefan
    Mani, Jens
    Stastny, Matthias
    Makarevic, Jasmina
    Juengel, Eva
    Tsaur, Igor
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 265 - 272
  • [33] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Stefan Vallo
    Jens Mani
    Matthias Stastny
    Jasmina Makarević
    Eva Juengel
    Igor Tsaur
    Georg Bartsch
    Axel Haferkamp
    Roman A. Blaheta
    Investigational New Drugs, 2013, 31 : 265 - 272
  • [34] A drug interaction study between ketoconazole and panobinostat (LBH589), an orally active histone deacetylase inhibitor, in patients with advanced cancer
    DeJonge, M.
    Woo, M. M.
    Van der Biessen, D.
    Hamberg, P.
    Sharma, S.
    Chen, L. C.
    Myke, N.
    Zhao, L.
    Hirawat, S.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] A novel therapeutic combination with synergistic antitumor activity in colon cancer: The dual tyrosine kinase inhibitor lapatinib and the histone deacetylase inhibitor LBH589
    LaBonte, Melissa J.
    Wilson, Peter M.
    El-Khoueiry, Anthony
    Lenz, Heinz -Josef
    Ladner, Robert D.
    CANCER RESEARCH, 2010, 70
  • [36] Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation
    Zhou, Qun
    Atadja, Peter
    Davidson, Nancy E.
    CANCER BIOLOGY & THERAPY, 2007, 6 (01) : 64 - 69
  • [37] Combination therapy targeting hypoxia inducible factor-α ( HIF-1 α) and Tissue Factor (TF) by the mTOR inhibitor Rapamycin and the histone deacetylase inhibitor LBH589
    Verheul, Henk M. W.
    Qian, David Z.
    Van Erp, Karen
    Salumbides, Brenda
    Sanni, Tolib
    Atadja, Peter
    Pili, Roberto
    CANCER RESEARCH, 2006, 66 (08)
  • [38] Histone Deacetylase Inhibitor LBH589 (Panobinostat) Suppresses the Activated-NFκB Pathway in Acquired Aromatase Inhibitor Resistant Breast Cancer Cells
    Kubo, M.
    Kanaya, N.
    Liu, Z.
    Chen, S.
    CANCER RESEARCH, 2011, 71
  • [39] The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells
    Lisiero, Dominique N.
    Soto, Horacio
    Everson, Richard G.
    Liau, Linda M.
    Prins, Robert M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
  • [40] A Phase Trial Evaluating the Use of a Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients with Acute Graft Versus Host Disease
    Perez, Lia Elena
    Fernandez, Hugo
    Tomblyn, Marcie
    Locke, Frederick
    Field, Teresa
    Pidala, Joseph
    Elmer, Erika
    Beato, Francisca
    Anasetti, Claudio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S337 - S338
12345